Episode 76 - HS Management Insights from SF Derm Society 2024 Annual Meeting | The Future of Dermatology Podcast

Summary In this episode of the Future of Dermatology podcast, we revisit the SF Derm 2024 Annual meeting and hear from Dr. Haley Naik, MD, as she discusses the management of Hidradenitis Suppurativa (HS). Dr. Naik covers the importance of controlling inflammation with medical therapies, the role of biologics in treatment, and the clinical pearls for using TNF inhibitors effectively. She emphasizes the need for early intervention to prevent permanent disfigurement and the importance of optimizing medical management before considering surgical options. Takeaways Using medical therapies to control inflammation is crucial. When to start a biologic is a common question. Preventing permanent disfigurement is a key goal. Adalimumab was the first FDA approved drug for HS. Real world goals include reducing pain and symptoms. Complete response means no pain and no new lesions. Infliximab is the best biologic for moderate to severe HS. Layering therapies is important for effective management. Optimizing medical management is essential before surgery. Chapters 00:00 - Introduction to the Future of Dermatology Podcast 01:03 - Managing Hidradenitis Suppurativa (HS) with Medical Therapies 04:35 - Understanding Biologics in HS Treatment 09:17 - Clinical Pearls for TNF Inhibitors in HS 11:35 - Optimizing HS Management Before Surgery